Erasca (NASDAQ:ERAS) Hits New 52-Week High – Time to Buy?

Shares of Erasca, Inc. (NASDAQ:ERAS) reached a new 52-week high on Monday . The company traded as high as $16.00 and last traded at $15.76, with a volume of 4133754 shares. The stock had previously closed at $15.47.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ERAS shares. Morgan Stanley set a $10.00 price target on Erasca in a report on Monday, January 26th. HC Wainwright raised their target price on Erasca from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a report on Thursday, January 22nd. Piper Sandler raised their price objective on shares of Erasca from $5.00 to $11.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Finally, Guggenheim reissued a “buy” rating and issued a $12.00 target price on shares of Erasca in a research note on Tuesday, January 27th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.22.

Erasca Stock Performance

The firm has a market cap of $4.88 billion, a price-to-earnings ratio of -35.02 and a beta of 1.16. The business’s 50-day moving average is $10.11 and its 200-day moving average is $5.14.

Insider Activity at Erasca

In related news, General Counsel Ebun Garner sold 120,000 shares of Erasca stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total value of $670,800.00. Following the completion of the sale, the general counsel directly owned 25,076 shares in the company, valued at $140,174.84. This trade represents a 82.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Morris sold 20,000 shares of Erasca stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $15.04, for a total transaction of $300,800.00. The SEC filing for this sale provides additional information. 14.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Affinity Asset Advisors LLC lifted its stake in Erasca by 22.3% in the second quarter. Affinity Asset Advisors LLC now owns 4,085,787 shares of the company’s stock valued at $5,189,000 after buying an additional 744,268 shares during the period. Savant Capital LLC acquired a new stake in shares of Erasca in the 2nd quarter valued at approximately $87,000. Frazier Life Sciences Management L.P. boosted its stake in Erasca by 0.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 22,729,436 shares of the company’s stock worth $28,866,000 after acquiring an additional 153,585 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in Erasca by 180.8% during the second quarter. Dynamic Technology Lab Private Ltd now owns 29,177 shares of the company’s stock valued at $37,000 after purchasing an additional 18,788 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in Erasca in the second quarter valued at approximately $45,000. Institutional investors and hedge funds own 67.78% of the company’s stock.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.